Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$19.31M+13.3%$16.99M+27.6%$17.63M+30.4%$17.86M+44.8%$17.05M+52.9%
$5.12M0.0%$4.94M-0.2%$5.26M+9.4%$4.95M+28.3%$5.12M+42.7%
$24.43M+10.2%$21.93M+20.1%$22.9M+24.9%$22.81M+40.9%$22.17M+50.4%
-$24.43M-10.2%-$21.93M-20.1%-$22.9M-24.9%-$22.81M-40.9%-$22.17M-53.0%
$914K-50.9%$1.16M-46.6%$1.37M+58.6%$1.56M+194%$1.86M+252%
-$23.52M-15.8%-$20.77M-29.1%-$21.53M-23.2%-$21.25M-19.1%-$20.31M-45.5%
-$0.95-14.5%-$0.84-$0.88+4.3%-$0.87+96.0%-$0.83+95.2%
-$23.76M-10.3%-$21.27M-20.5%-$22.24M-25.6%-$22.17M-42.2%-$21.54M-54.9%
-$24.43M-10.2%-$21.93M-20.1%-$22.9M-24.9%-$22.81M-40.9%-$22.17M-53.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Artiva Biotherapeutics, Inc. profitable?
Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
What is Artiva Biotherapeutics, Inc.'s earnings per share?
Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.